Yiling Pharma owns three manufacturing sites for API and Formulation products. Yiling’s technical team drives projects from pre-formulation development to commercial scale manufacture,and have finished over 30+ site transfer projects,10+ new drug projects of small batches for clinical trial,and submitted 13 ANDAs to US FDA.The annual capacity of Formulation sites exceeds 6.4 billion units,and will expand to 26.4 billion units recently,and capability of injection(0.42 billion vial/ampoule)will join soon.
Manufacturing Facility
